Literature DB >> 32265611

Valproic Acid Induced Pancreatitis Presenting With Decreased Level of Consciousness in a Child With Tuberous Sclerosis Complex.

Pierre-Charles Deschenes, Julie Autmizguine, Philippe Major, Niina Kleiber.   

Abstract

A 2-year-old Caucasian boy with tuberous sclerosis complex presented to the emergency department with lethargy and new onset myoclonias. Pancreatitis, thrombocytopenia, and coagulopathy associated to a decreased level of consciousness were diagnosed. Valproic acid had been initiated 13 months before and had been slowly increased to a dose of approximately 38 mg/kg/day. All the symptoms resolved after discontinuation of the medication. The clinical presentation of this child highlights that valproic acid-related pancreatitis can present with decreased level of consciousness without associated gastrointestinal symptoms. Adverse drug reactions associated with valproic acid can lead to damage of multiple organs and may prove fatal if not promptly recognized and managed. Copyright Pediatric Pharmacy Association. All rights reserved. For permissions, email: mhelms@pediatricpharmacy.org 2020.

Entities:  

Keywords:  adverse drug effect; adverse drug reaction; pancreatitis; seizures; side effect; tuberous sclerosis complex; valproic acid

Year:  2020        PMID: 32265611      PMCID: PMC7134590          DOI: 10.5863/1551-6776-25.3.256

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


  15 in total

1.  Valproate-induced hyperammonemic encephalopathy: an update on risk factors, clinical correlates and management.

Authors:  Amit Chopra; Bhanu Prakash Kolla; Meghna P Mansukhani; Pamela Netzel; Mark A Frye
Journal:  Gen Hosp Psychiatry       Date:  2012-02-02       Impact factor: 3.238

2.  The spectrum of valproic acid-associated pancreatitis.

Authors:  Steven L Werlin; Daryl L Fish
Journal:  Pediatrics       Date:  2006-10       Impact factor: 7.124

Review 3.  Valproic acid-induced acute pancreatitis in pediatric age: case series and review of literature.

Authors:  M Cofini; F Quadrozzi; P Favoriti; M Favoriti; G Cofini
Journal:  G Chir       Date:  2015 Jul-Aug

Review 4.  Pediatric Off-Label and Unlicensed Drug Use and Its Implications.

Authors:  Rajeshwari Gore; Preeta K Chugh; Chakra D Tripathi; Yangshen Lhamo; Sandhya Gautam
Journal:  Curr Clin Pharmacol       Date:  2017

5.  Surveillance for fatal suspected adverse drug reactions in the UK.

Authors:  A Clarkson; I Choonara
Journal:  Arch Dis Child       Date:  2002-12       Impact factor: 3.791

6.  Valproate-mediated disturbances of hemostasis: relationship to dose and plasma concentration.

Authors:  B Gidal; N Spencer; M Maly; M Pitterle; E Williams; M Collins; J Jones
Journal:  Neurology       Date:  1994-08       Impact factor: 9.910

Review 7.  Acute pancreatitis in children from Valproic acid: case series and review.

Authors:  Nancy L Grauso-Eby; Olga Goldfarb; Lori B Feldman-Winter; Gary N McAbee
Journal:  Pediatr Neurol       Date:  2003-02       Impact factor: 3.372

8.  Trends in Off-Label Drug Use in Ambulatory Settings: 2006-2015.

Authors:  Divya Hoon; Matthew T Taylor; Pooja Kapadia; Tobias Gerhard; Brian L Strom; Daniel B Horton
Journal:  Pediatrics       Date:  2019-09-16       Impact factor: 7.124

9.  A prospective study of adverse drug reactions to antiepileptic drugs in children.

Authors:  Mark Anderson; Oluwaseun Egunsola; Janine Cherrill; Claire Millward; Apostolos Fakis; Imti Choonara
Journal:  BMJ Open       Date:  2015-06-01       Impact factor: 2.692

Review 10.  Valproic acid and fatalities in children: a review of individual case safety reports in VigiBase.

Authors:  Kristina Star; I Ralph Edwards; Imti Choonara
Journal:  PLoS One       Date:  2014-10-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.